Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 13 - Leveraging disruptive technologies to drive innovation in CNS clinical drug development

Summary

This chapter addresses general Phase II clinical development issues and pitfalls and the relationship of Phase II to the preceding and subsequent phases of development, and then focuses on the new issues introduced into Phase II development by the emergence of personalized medicine. The dosing frequency to test should be derived from preclinical data and from human biomarker evidence of the development of and recovery from tolerance to intended effect. Indication selection, matching targets to patients, can be facilitated by collecting appropriate genetic or other biological information about the proposed subject population, and assuring that the biology of the subjects is matched to the drug candidate's proposed mechanism. Biomarker technologies have proven their mettle in a number of applications, and practical methods are now available that enable the drug development process. CNS drug developers and their development plans need to adapt to incorporate the changes brought by personalized medicines.

References

Adams, C. P. and Brantner, V. V. (2010). Spending on new drug development. Health Econ, 19, 130–41.
Cramer, J. and Rosenheck, R. (1998). Compliance with medication regimens for mental and physical disorders. Psychiatr Serv, 49, 196–201.
Cutler, D. M. (2007). The demise of the blockbuster?New Engl J Med, 356, 13.
Dooren, J. C. (2011). A clinical drug trial via phone, computer. Wall Street Journal, http://online.wsj.com/article/SB10001424052702304432304576369840721708396.html.
Eichler, H. G., Blooechl-Daum, B., and Abadie, E. (2010). Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev, 9, 277–91.
Jack, A. (2009). Novartis chip to help ensure bitter pills are swallowed. Financial Times, 21 September.
Kenkeremath, N. (2008). Clinical research and drug safety provisions of the FDA Amendments Act of 2007: trends, opportunities and challenges. A report prepared for ACRO by Leading Edge Policy and Strategy, LLC, 8 August.
Lieberman, J. A., Stroup, S., and McEvoy, J. P. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med, 353, 1209–23.
Manschreck, T. C. and Boshes, R. A. (2007). The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiat, Sep-Oct, 15 (5), 245–58.
Saxon, L. A. and Gilliam, R. (2010). Long-term outcome after ICD and CRT implantation and influence of remote device follow-up. The ALTITUDE Survival Study. Circulation, 122, 2359–67.
Van Someren Eus, J., et al. (2006). New actigraph for long-term tremor recording. Movement Disord, 21, 1136–43.